Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

SAN FRANCISCO, Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, in atopic dermatitis has been accepted for a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. The meeting will be held in Orlando, USA, from November 6 to 10, 2025.

Read more at prnewswire.com